Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood markers may predict liver transplant complications

NCT ID NCT07875595

Knowledge-focused Sponsor: Hospital Italiano de Buenos Aires Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 15, 2026 · Last updated Oct 16, 2026 · Updated 1 time

Summary

Researchers are studying blood samples from 60 adults who receive a liver transplant to see how immune markers change over the first year. The study measures cytokines, interferons, immunoglobulins, lymphocyte populations, and other immune signals before transplant and at set times afterward. The goal is to learn whether these markers are linked to infections, organ rejection, or viral reactivation. Biomarker results are for research only and do not change patient care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If immune markers reliably track complications, doctors could one day tailor immunosuppression doses to each liver transplant patient instead of using standard regimens.
What could go wrong
This observational study cannot prove that biomarkers cause or prevent complications, and it does not change any patient's treatment. Results may not hold up in larger or more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult liver transplant recipients treated at Hospital Italiano de Buenos Aires, Hospital Universitario Austral, or Hospital Alemán de Buenos Aires.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age 18 years or older. Adult patients admitted to the intensive care unit after liver transplantation. Exclusion Criteria: Refusal to participate in the study. Liver transplantation performed for acute liver failure (fulminant hepatitis).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biomarkers / blood are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections infectious disease Rejection, Psychology

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biomarkers / blood Immuno-suppression Infections Liver transplantation (LT) Rejection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Aleman

    RECRUITING

    Buenos Aires, Buenos Aires F.D., C1118AAT, Argentina

  • Hospital Italiano de Buenos Aires

    RECRUITING

    Buenos Aires, Buenos Aires F.D., 1199, Argentina

  • Hospital Universitario Austral

    RECRUITING

    Pilar, Buenos Aires, B1629, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.